Tratamento de verrugas virais com bleomicina intralesional

Noriega, Leandro Fonseca; Valandro, Letícia dos Santos; Chiacchio, Nilton Gioia Di; Vieira, Marcelo Carvalho; Chiacchio, Nilton Di

doi:10.5935/scd1984-8773.201810103

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, none of them had serious adverse effects. These findings are comparable to other reports [ 9 , 12 – 18 ]. One previous study detected reversible necrosis in 1.2% of the patients with IL bleomycin injected for ungual warts [ 19 ].…”

Section: Discussionsupporting

confidence: 92%

Intralesional Bleomycin for the Treatment of Resistant Palmoplantar and Periungual Warts

Marahatta

Khadka

Agrawal

et al. 2021

Dermatology Research and Practice

View full text Add to dashboard Cite

Introduction. Periungual, palmar, and plantar warts are difficult to treat with poor treatment response. Intralesional (IL) bleomycin has shown promising results for their treatment in a few reports. However, we need further evidence before opting it for treating difficult sites and resistant warts. Hence, we conducted this study to assess the efficacy and safety of IL bleomycin for the treatment of resistant palmoplantar and periungual warts. Methods. In this retrospective study, we included all patients who were given IL bleomycin for warts over a year. Maximum three sittings of bleomycin (1 mg/ml) were given monthly, and they were followed up for 3 months after the procedure. The response was categorized as complete, near-complete, significant, moderate, mild, and no clearance for 100%, 75–99%, 50–74%, 25–49%, 1–25%, and 0% clearance, respectively. Results. Out of 29 patients, follow-up details were available only in 19 patients (53 warts). The mean duration was 2.5 ± 1.47 years. The number of past interventions ranged from 2–4. Wart clearance after the first intervention was complete in 36.84%, near-complete in 26.31%, significant in 26.31%, and moderate in 10.53%. Wart clearance after the last intervention was complete in 89.47% and near-complete in 10.52% of patients. However, during 3 months of follow-up after the last injection, 15.78% had a recurrence. None of them had severe local and systemic side effects. Conclusions. IL bleomycin could be a better treatment option for the treatment of resistant and difficult warts. However, we observed a higher recurrence rate even in a shorter follow-up. Hence, we need further studies with larger samples.

show abstract

Section: Discussionsupporting

confidence: 92%

Intralesional Bleomycin for the Treatment of Resistant Palmoplantar and Periungual Warts

Marahatta

Khadka

Agrawal

et al. 2021

Dermatology Research and Practice

View full text Add to dashboard Cite

show abstract

“…Those cells are associated with this type of hypersensitive response. The intralesional immunotherapy will have a significant effect on the wart tissue and other tissues around lesion [8,64,65].…”

Section: Intralesional Immunotherapymentioning

confidence: 99%

The role of intralesional immunotherapy in Condyloma Acuminata

Lita Setyowatie,

Putri Mulia Bela Grania Hasibuan

2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Intralesional immunotherapy is one of the immunotherapy modalities that can be given to patients with condyloma acuminata (CA) with a high success rate both in inhibiting progression and preventing recurrence of genital warts. Intralesional immunotherapy regimens that are currently being studied are the use of vaccines and cytokines. Some of the antigens studied for use as therapy in genital warts include Candida albicans, measles, mumps and rubella (MMR), and Tuberculin/Purified Protein Derivate (PPD), Mycobacterium w, and Bacille Calmette-Guerin (BCG). Vaccines and cytokines work by inducing a delayed-type hypersensitivity response to warts tissue, both through cellular and humoral immune responses, mediated by CD8+ T lymphocytes, CD4+ T lymphocytes, B lymphocytes and regulatory T cells so that this can eliminate HPV virus infection in CA. This literature review aims to provide an understanding of the use of intralesional immunotherapy as an effective alternative therapy in CA.

show abstract

Tratamento de verrugas virais com bleomicina intralesional

Cited by 2 publications

References 0 publications

Intralesional Bleomycin for the Treatment of Resistant Palmoplantar and Periungual Warts

Intralesional Bleomycin for the Treatment of Resistant Palmoplantar and Periungual Warts

The role of intralesional immunotherapy in Condyloma Acuminata

Contact Info

Product

Resources

About